相关实验视频

Updated: May 3, 2026

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Published on: March 2, 2011

肌痛性骨髓灰质炎中血清中介质素-39的升高:一种可能的生物标志物

Kun Jia¹, Yingzhe Shao², Xuan Liu³

¹Department of Neurology, Tianjin Huanhu Hospital, Tianjin, China.

European journal of medical research

|March 3, 2026

概括

血清干白素-39 (IL-39) 水平在活跃的严重肌痛性肌痛症 (MG) 中升高,并且随着缓解而降低. 这种细胞因子可能表明MG患者的一般免疫激活.

科学领域:

免疫学免疫学免疫学
自免疫性疾病自免疫性疾病
生物标志物发现发现

背景情况:

洲际蛋白-39 (IL-39) 是一种参与免疫调节和自身免疫性疾病的细胞因子.
之前尚未确定IL-39在肌痛性骨髓灰质炎 (MG) 中的作用.
研究MG中的IL-39可能会揭示对疾病发病的新见解.

研究的目的:

在患有乙胆受体 (AChR) 抗体阳性骨髓灰质炎 (MG) 的患者中确定血清IL-39水平.
评估IL-39水平与MG的疾病活性之间的关联.
评估IL-39作为MG的潜在生物标志物.

主要方法:

在51名ACHR+MG患者和43名健康对照中使用ELISA量化血清IL-39.
对20名MG患者的样本进行了纵向分析,这些患者实现了缓解.
临床严重程度是使用每日生活 (MG-ADL) 的Myasthenia Gravis活动得分来评估的.

主要成果:

血清IL-39水平与健康对照组相比,活跃的MG患者的血清IL-39水平显著更高 (p < 0.001).
在临床缓解期间,IL-39水平显著下降 (p < 0.001).
IL-39显示出高的诊断准确性 (AUC = 0.922),但与MG-ADL得分没有相关性.

结论:

血清IL-39水平与AChR+ MG中的疾病活性有动态联系.
随着临床缓解,IL-39水平下降,这表明它在疾病状态监测中的作用.
IL-39可能反映了一般免疫激活,而不是特定的MG诊断或严重程度.

关键词:

生物标志物生物标志物相对应关系相对应关系艾丽莎·伊丽莎·伊丽莎互乐金-39是一种抗体.骨髓灰质炎 (Myasthenia gravis) 是一个严重的疾病.在ROC曲线上,ROC曲线

更多相关视频

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

相关概念视频

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...